skip to main content

Prevention Program for People Living with Stroke in Low and Middle-Income Country: A Systematic Review

*Aisyah Lahdji  -  Doctoral Study Program of Medical and Health Science, Faculty of Medicine, Universitas Diponogoro, Indonesia
Dwi Pudjonarko  -  Department of Neurology, Faculty of Medicine, Universitas Diponegoro, Indonesia
Zahroh Shaluhiyah  -  Department of Health Promotion, Faculty of Public Health, Universitas Diponegoro, Indonesia
Open Access Copyright (c) 2024 Jurnal Promosi Kesehatan Indonesia

Citation Format:

Background: Non-communicable diseases (NCDs) are the primary factors responsible for mortality and impairment on a global scale. By 2030, it is estimated that non-communicable diseases will comprise 80% of the global population. According to the World Health Organization (WHO), the risk of stroke will grow by 50% for the entire global population by 2022. Currently, it is projected that 1 in 4 individuals will suffer from a stroke

Method: This review was reported using the “Preferred Reporting Items for Systematic Reviews and Meta-Analysis” guideline and written using the “Synthesis without Meta-Analysis” method. The included studies for this review followed several criteria, including randomized controlled trials (RCT), English and Bahasa articles, using population was people living with stroke, intervention was any prevention and disability limitation, and outcomes were prevention measurements (primary, secondary, and tertiary prevention).

Results: The study yielded multiple efficacious and streamlined preventive interventions implemented for stroke patients. Emphasizing risk factors as the main strategy for preventing health issues, using pharmacological treatments such as polypill, aspirin, and vitamins as a supplementary measure under the guidance of medical physicians and cardiologists. In addition, tertiary preventive initiatives encompass more than just administering drug treatment; they also require adherence to pharmaceutical protocols

Fulltext View|Download
Keywords: prevention program;stroke;low income country;middle income country;systematic review

Article Metrics:

  1. Bennett JE, Stevens GA, Mathers CD, Bonita R, Rehm J, Kruk ME, et al. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Vol. 392, The Lancet. Lancet Publishing Group; 2018. p. 1072–88
  2. WHO. World Health Organization. 2022. Word Stroke Day 2022
  3. Lilipory M, Pattipelohy MH, Tuarissa YS. Motivasi dan Sumber Informasi Berhubungan dengan Pencegahan Stroke Berulang. Moluccas Health Journal. 2019 Dec 14;1(3)
  4. Alharbi M, Alharbi A, Alamri M, Alharthi A, Alqerafi A, Alharbi M. Ischemic stroke: prevalence of modifiable risk factors in the Saudi population. International Journal of Medicine in Developing Countries. 2019;601–3
  5. Pennlert J. Recurrent Stroke: Risk Factors, Prevention, and Prognosis. [Umea]: Umea University; 2016
  6. Zhang J, Zhu P, Liu B, Yao Q, Yan K, Zheng Q, et al. Time to recurrence after first-ever ischaemic stroke within 3 years and its risk factors in Chinese population: a prospective cohort study. BMJ Open. 2019 Dec 18;9(12):e032087
  7. Ramdani ML. Karakteristik dan Periode Kekambuhan Stroke pada Pasien dengan Stroke Berulang di Rumah Sakit Margono Soekardjo Purwokerto Kabupaten Banyumas. Jurnal Keperawatan Muhammadiyah. 2018 Jun 30;3(1)
  8. Yi Ying C, Harith S, Ahmad A, Basri Mukhali H. Prevalence, risk factors and secondary prevention of stroke recurrence in eight countries from south, east and southeast asia: a scoping review. Medical Journal of Malaysia. 2018 Apr 22;73(2):90–9
  9. Sang Oh J, Gun Bae H, Geun Oh H, Mann Yoon S, Doh JW, Seok Lee K. The Changing Trends in Age of First-Ever or Recurrent Stroke in A Rapidly Developing Urban Area during 19 Years. J Neurol Neurosci. 2017;08(04)
  10. Trisetiawati L, Yuniar P, . B. Recurrent Stroke among Patients at Indonesia’s National Brain Center Hospital: Contributing Factors. KnE Life Sciences. 2018 May 17;4(4):19
  11. Dopler B. Stroke Prevention. Dela J Public Health. 2023 Aug 31;9(3):6–10
  12. Silver B. MedScape. 2021. Stroke Prevention
  13. Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. The Lancet. 2019 Aug;394(10199):672–83
  14. Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. New England Journal of Medicine. 2021 Jan 21;384(3):216–28
  15. Sandset EC, Goldstein LB. Treatments-Preventive. Stroke. 2021 Mar;52(3):1118–20
  16. Doehner W, Mazighi M, Hofmann BM, Lautsch D, Hindricks G, Bohula EA, et al. Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. Eur J Prev Cardiol. 2020 May 30;27(7):682–92
  17. Nyoman N, Udayani W, Luh N, Dewi P, Sari P. Science Midwifery Effectiveness of Use of Antihypertensive Drug In Inpatient Stroke Patients In Hospital Tabanan Regency [Internet]. Vol. 10, Science Midwifery. Online; 2022. Available from:
  18. Kanagala V, Anusha A, Rao B, Challa S, Nalla K, Gadde R. A study of medication-related problems in stroke patients: A need for pharmaceutical care. J Res Pharm Pract. 2016;5(3):222
  19. Basheti IA, Ayasrah SM, Ahmad M. Identifying treatment related problems and associated factors among hospitalized post-stroke patients through medication management review: A multi-center study. Saudi Pharmaceutical Journal. 2019 Feb;27(2):208–19
  20. Herpich F, Rincon F. Management of Acute Ischemic Stroke. Crit Care Med. 2020 Nov;48(11):1654–63
  21. Dabhi N, Mastorakos P, Sokolowski JD, Kellogg RT, Park MS. Effect of drug use in the treatment of acute ischemic stroke: A scoping review. Surg Neurol Int. 2022 Aug 19;13:367
  22. Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, et al. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation. 2017 Sep 26;136(13):1193–203
  23. Shi X, He J, Lin M, Liu C, Yan B, Song H, et al. Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial. Am Heart J. 2021 Aug;238:45–58
  24. Karuniawati H, Ikawati Z, Gofur A. Pencegahan Sekunder untuk Menurunkan Kejadian Stroke Berulang pada 14-21 Stroke Iskemik. Journal of Management and Pharmacy Practice. 2015 Mar;5(1):14–21
  25. Yan LL, Li C, Chen J, Miranda JJ, Luo R, Bettger J, et al. Prevention, management, and rehabilitation of stroke in low- and middle-income countries. eNeurologicalSci. 2016 Mar;2:21–30
  26. Kalkonde Y V., Alladi S, Kaul S, Hachinski V. Stroke Prevention Strategies in the Developing World. Stroke. 2018 Dec;49(12):3092–7
  27. Parasad K, Srivastava P, Narayan S, Kumar V, Lal V, Bhatia R, et al. Guideline for Prevention Management Stroke. New Delhi; 2019 Jul
  28. Illinois Departement of Public Health. Illinois Departement of Public Health. 2023 [cited 2024 Feb 21]. p. 1–3 Illinois Health Disease and Stroke Prevention Program. Available from:
  29. Basri H, Puvanarajah SD, kee HF, Ibrahim KA, Chung LW, Irene L, et al. Clinical Practice Guidelines: Management of Ischaemic Stroke. 3rd ed. Kuala Lumpur, Malaysia: Malaysian Society of Neuroscience; 2020. 1–55 p

Last update:

No citation recorded.

Last update: 2024-05-22 14:29:22

No citation recorded.